Harness the power of artificial intelligence to remove time-consuming quantification and qualification tasks from your pathology workflow, allowing you to focus on more meaningful tasks.
The uPath image analysis algorithms for pathology decision support extract meaningful information from pathology slide images so that pathologists can quickly, accurately and confidently assess immunohistochemistry and in-situ hybridisation. Algorithms in the uPath image analysis algorithm suite provide image analysis of VENTANA slide scanner images stained with a Roche Tissue Diagnostics assay.
In 2011, Roche was the first company to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA) on our first generation image analysis algorithms (i.e., VENTANA Companion Algorithm HER2 (4B5))1. At the time, Roche was the only company in the industry offering a comprehensive portfolio of FDA-cleared image analysis algorithms and digital read applications for the five key immunohistochemistry (IHC) breast markers.2 Since then, the technology has evolved and we have launched three CE marked whole slide analysis image analysis algorithms, uPath HER2 (4B5) image analysis, Breast3, uPath HER2 Dual ISH image analysis, Breast3 and uPath PD-L1 (SP263) image analysis, NSCLC3. We also have our RUO uPath ER (SP1) image analysis, Breast4, uPath PR (1E2) image analysis, breast4 and uPath Ki-67 (30-9) image analysis, breast4 algorithms.
Roche is committed to aiding pathologists and will continue to deliver next-generation image analysis algorithms that provide pathologists with more tools to improve efficiency and precision.